Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression
Autore:
Benigni, A; Perico, N; Remuzzi, G;
Indirizzi:
Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy Mario Negri Inst Pharmacol Res Bergamo Italy I-24125 4125 Bergamo, Italy Osped Riuniti Bergamo, Unit Nephrol & Dialysis, I-24100 Bergamo, Italy Osped Riuniti Bergamo Bergamo Italy I-24100 ysis, I-24100 Bergamo, Italy
Titolo Testata:
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
fascicolo: 1, volume: 10, anno: 2001,
pagine: 1 - 6
SICI:
1062-4821(200101)10:1<1:ROREIP>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONVERTING ENZYME-INHIBITION; A RECEPTOR ANTAGONIST; URINARY-EXCRETION; ANGIOTENSIN-II; BLOOD-PRESSURE; DIABETIC NEPHROPATHY; DISEASE PROGRESSION; GENE-EXPRESSION; IMMUNOHISTOCHEMICAL DISTRIBUTION; PROLIFERATIVE NEPHRITIS;
Tipo documento:
Editorial Material
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
66
Recensione:
Indirizzi per estratti:
Indirizzo: Benigni, A Mario Negri Inst Pharmacol Res, Via Gavazzeni 11, I-24125 Bergamo, Italy Mario Negri Inst Pharmacol Res Via Gavazzeni 11 Bergamo Italy I-24125
Citazione:
A. Benigni et al., "Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression", CURR OP NEP, 10(1), 2001, pp. 1-6

Abstract

Proteinuria is one of the major risk factors for renal disease progressionin patients with chronic nephropathies. Studies in disease models have helped to delineate mechanisms leading to renal structural damage as a result of persistent dysfunction of the glomerular barrier to proteins, even when the primary immune or non-immune insult to the kidney has ceased. From these preclinical studies, a role for endothelin in proteinuric chronic renal diseases has been suggested, thus providing the rationale for novel therapeutic approaches with endothelin receptor antagonists to maximize renoprotection so far achieved with blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibition or angiotensin II receptor antagonism. Trials are needed to explore this potential area of clinical interest. Curr Opin Nephrol Hypertens 10:1-6. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/04/20 alle ore 02:27:05